New obesity drug survodutide aims to rev up metabolism in head-to-head trial
NCT ID NCT06745284
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This study tests whether survodutide, a new medicine, helps people with obesity burn more energy and fat compared to semaglutide. About 64 adults aged 18-65 with a BMI between 30 and 45 will receive weekly injections for several months. Researchers will measure energy use in a special room to see how the body responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth - Translation Research Institute
Orlando, Florida, 32804, United States
-
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
Conditions
Explore the condition pages connected to this study.